Myotonic dystrophy type 1.
Department of Paediatrics (Nguyen), London Health Sciences Centre; Paediatric Neurology Clinic (Campbell), Children's Hospital, London Health Sciences Centre; Department of Epidemiology and Clinical Neurological Sciences, Western University, London, Ont.
Cam-Tu Emilie
CE
Nguyen
Department of Paediatrics (Nguyen), London Health Sciences Centre; Paediatric Neurology Clinic (Campbell), Children's Hospital, London Health Sciences Centre; Department of Epidemiology and Clinical Neurological Sciences, Western University, London, Ont. craig.campbell@lhsc.on.ca.
Craig
C
Campbell
D017668:Age of Onset; D020132:Anticipation, Genetic / Q000235:genetics; D001145:Arrhythmias, Cardiac / Q000401:mortality / Q000503:physiopathology*; D002423:Cause of Death; D006801:Humans; D008801:Mexiletine / Q000627:therapeutic use; D009223:Myotonic Dystrophy / Q000188:drug therapy / Q000453:epidemiology / Q000235:genetics / Q000503:physiopathology*; D061567:Voltage-Gated Sodium Channel Blockers / Q000627:therapeutic use
D061567:Voltage-Gated Sodium Channel Blockers; D008801:Mexiletine